Form 13-F position report

PARATEK PHARMACEUTICALS INC

Reported by Bruce & Co Inc

PRTK CUSIP 699374AA2 Manager CIK 0001358331

Reported 16,600,000 shares, unchanged from the prior quarter.

Reported value 32.5%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 4.56% This manager · Q2 2023
Shares 16,600,000 Quarter-end amount reported
Reported value $16,268,000 Fair value at quarter end
Consecutive quarters held 21 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 15272000
2022-03-31 14608000
2022-06-30 14276000
2022-09-30 14774000
2022-12-31 14442000
2023-03-31 12280252
2023-06-30 16268000
2023-09-30 8415000
2023-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

9 quarters
Quarterly reported position history for PARATEK PHARMACEUTICALS INC held by Bruce & Co Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2023 Reduced 0 -8,500,000 (-100.0%) 0 $0 2024-02-12
Q3 2023 Reduced 8,500,000 -8,100,000 (-48.8%) 2.87% $8,415,000 2023-11-13
Q2 2023 Unchanged 16,600,000 0 (0.0%) 4.56% $16,268,000 2023-08-08
Q1 2023 Unchanged 16,600,000 0 (0.0%) 3.35% $12,280,252 2023-05-12
Q4 2022 Unchanged 16,600,000 0 (0.0%) 3.72% $14,442,000 2023-02-15
Q3 2022 Unchanged 16,600,000 0 (0.0%) 4.06% $14,774,000 2022-11-15
Q2 2022 Unchanged 16,600,000 0 (0.0%) 3.36% $14,276,000 2022-08-09
Q1 2022 Unchanged 16,600,000 0 (0.0%) 2.99% $14,608,000 2022-05-11
Q4 2021 Unchanged 16,600,000 0 (0.0%) 3.05% $15,272,000 2022-02-16
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1 manager reported PARATEK PHARMACEUTICALS INC for Q2 2023.

Managers reporting PARATEK PHARMACEUTICALS INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bruce & Co Inc This report Unchanged 16,600,000 0 4.56% $16,268,000 21 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 08, 2023
Filing type
13F-HR
Position type
Cv 4.75%

Voting authority reported

Sole
16,600,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.